Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 10 2025
0mins
Should l Buy ERNA?
Source: NASDAQ.COM
Reverse Stock Split Announcement: Ernexa Therapeutics will execute a 1-for-15 reverse stock split effective June 12, 2025, to comply with Nasdaq's minimum bid requirement, reducing outstanding shares from approximately 110.4 million to about 7.36 million.
Impact on Shareholders: The reverse split will not change the rights or preferences of the common stock, and shareholders entitled to fractional shares will receive one whole share instead; trading will continue under the ticker symbol "ERNA."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERNA
About ERNA
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Rise, AutoNation Shares Surge
- Market Performance: U.S. stocks traded higher midway through trading, with the S&P 500 gaining approximately 1.6%, the Dow rising 2.01% to 49,891.59, and the NASDAQ climbing 1.84% to 22,954.50, indicating a positive market sentiment and increased investor confidence.
- Sector Dynamics: Information technology shares gained 2.5% on Friday, while communication services stocks fell by 2%, reflecting a preference for tech stocks and concerns over the communication sector, which may impact future performance of related companies.
- AutoNation Earnings: Shares of AutoNation, Inc. (NYSE:AN) surged over 7% after posting fourth-quarter results, reporting adjusted earnings per share of $5.08, a 2% year-over-year increase that beat analyst expectations of $4.85, despite sales of $6.929 billion missing the consensus estimate of $7.200 billion, showcasing the company's resilience in profitability.
- Economic Indicators: The U.S. Manheim Used Vehicle Value Index rose 2.4% month-over-month in January, while the University of Michigan's consumer sentiment index increased by 0.9 points to 57.3, exceeding market estimates of 55, indicating a rebound in consumer confidence that could positively influence future spending.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 600 Points
- Strong Dow Performance: The Dow Jones index surged over 600 points on Friday, gaining 1.29% to close at 49,537.77, indicating a robust market rebound that may attract more investor interest.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.97% to 22,759.56, while the S&P 500 rose 1.02% to 6,867.68, reflecting a recovery trend in tech and other sectors, thereby boosting market confidence.
- Amazon's Earnings Impact Stock Price: Amazon.com Inc. (NASDAQ:AMZN) shares fell around 9% on Friday despite reporting fourth-quarter net sales of $213.39 billion, a 14% year-over-year increase; however, its earnings per share of $1.95 missed the consensus estimate of $1.97, leading to diminished investor confidence.
- Commodity Market Fluctuations: Oil prices dipped 0.3% to $63.08, while gold rose 1.6% to $4,969.10, indicating increased demand for safe-haven assets, and copper saw a slight increase of 0.4% to $5.8460, reflecting stable industrial demand.
See More
Ernexa Therapeutics Prices Public Offering at $0.50 per Share
- Offering Size: Ernexa Therapeutics announced a public offering of 21,000,000 shares at a price of $0.50 per share, expected to generate approximately $10.5 million in gross proceeds, which will be utilized to advance development programs and for general corporate purposes.
- Warrant Details: The accompanying warrants have an exercise price of $0.68 per share, are exercisable upon issuance, and will expire either five years after the initial issuance or 180 days following the release of clinical trial data, potentially adding another $14.3 million in gross proceeds if fully exercised.
- Underwriter Role: Brookline Capital Markets is acting as the exclusive placement agent for the offering, facilitating the capital raise to support Ernexa's innovative therapeutic solutions and ensuring the funds are secured for ongoing development.
- Technological Background: Ernexa focuses on developing cell therapies for advanced cancer and autoimmune diseases, leveraging engineered induced pluripotent stem cells (iPSCs) to provide scalable, off-the-shelf treatment solutions, highlighting significant market potential in the healthcare sector.
See More
Ernexa Therapeutics Advances Cell Therapy for Cancer Treatment
- Successful FDA Meeting: Ernexa Therapeutics recently held a successful Pre-IND meeting with the U.S. FDA, receiving regulatory alignment on its lead cell therapy ERNA-101, paving the way for an Investigational New Drug application and anticipated clinical trials in the second half of 2026.
- Accelerated Technology Transfer: The company has initiated technology transfer for clinical-grade manufacturing, which not only speeds up operational readiness but also lays a solid foundation for clinical testing of ERNA-101, demonstrating Ernexa's forward-looking strategy in cell therapy.
- Innovative Cell Therapy: ERNA-101 is designed to activate and regulate the immune system to recognize and attack cancer cells, representing Ernexa's core technology in treating ovarian cancer and autoimmune diseases, with significant market potential.
- New Treatment Solutions: Ernexa's synthetic allogeneic induced mesenchymal stem cells (iMSCs) provide a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting, marking a significant advancement in cell therapy.
See More
Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%
- Earnings Beat: Penguin Solutions reported Q1 earnings of $0.49 per share, surpassing analyst expectations of $0.44, indicating robust profitability that may attract more investor interest.
- Sales Growth: The company achieved quarterly sales of $343.071 million, exceeding the analyst consensus of $338.758 million, reflecting strong market demand and potential for sustained growth.
- Stock Price Surge: Following the earnings report, Penguin Solutions' shares rose 5.3% to $22.70 in pre-market trading, demonstrating a positive market reaction to its financial performance.
- Increased Market Confidence: The positive results not only bolster investor confidence but may also enhance the company's prospects for better terms in future financing and expansion plans.
See More
Ernexa Therapeutics Targets 2026 for First-in-Human Ovarian Cancer Trial
- Regulatory Alignment Achieved: Ernexa Therapeutics received positive feedback during its Pre-IND meeting with the FDA, establishing a clear pathway for IND submission and aiming to initiate its first-in-human ovarian cancer trial in the second half of 2026, marking a significant advancement in cancer treatment.
- Accelerated Tech Transfer: The company has commenced critical tech transfer, a milestone that will expedite the preparation of clinical-grade materials, ensuring efficient operations ahead of clinical trials and enhancing its competitive edge in the cell therapy market.
- Clear Product Focus: Ernexa's lead clinical product, ERNA-101, targets ovarian cancer, a field with limited effective therapies and high recurrence rates, positioning the company to address unmet patient needs with its innovative treatment approach.
- Strategic Vision Defined: By developing synthetic allogeneic induced mesenchymal stem cells (iMSCs), Ernexa not only enhances treatment accessibility but also lays the groundwork for future product line expansions, showcasing the company's long-term growth potential in the cell therapy sector.
See More
U.S. Stocks Rise, AutoNation Shares Surge
- Market Performance: U.S. stocks traded higher midway through trading, with the S&P 500 gaining approximately 1.6%, the Dow rising 2.01% to 49,891.59, and the NASDAQ climbing 1.84% to 22,954.50, indicating a positive market sentiment and increased investor confidence.
- Sector Dynamics: Information technology shares gained 2.5% on Friday, while communication services stocks fell by 2%, reflecting a preference for tech stocks and concerns over the communication sector, which may impact future performance of related companies.
- AutoNation Earnings: Shares of AutoNation, Inc. (NYSE:AN) surged over 7% after posting fourth-quarter results, reporting adjusted earnings per share of $5.08, a 2% year-over-year increase that beat analyst expectations of $4.85, despite sales of $6.929 billion missing the consensus estimate of $7.200 billion, showcasing the company's resilience in profitability.
- Economic Indicators: The U.S. Manheim Used Vehicle Value Index rose 2.4% month-over-month in January, while the University of Michigan's consumer sentiment index increased by 0.9 points to 57.3, exceeding market estimates of 55, indicating a rebound in consumer confidence that could positively influence future spending.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 600 Points
- Strong Dow Performance: The Dow Jones index surged over 600 points on Friday, gaining 1.29% to close at 49,537.77, indicating a robust market rebound that may attract more investor interest.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.97% to 22,759.56, while the S&P 500 rose 1.02% to 6,867.68, reflecting a recovery trend in tech and other sectors, thereby boosting market confidence.
- Amazon's Earnings Impact Stock Price: Amazon.com Inc. (NASDAQ:AMZN) shares fell around 9% on Friday despite reporting fourth-quarter net sales of $213.39 billion, a 14% year-over-year increase; however, its earnings per share of $1.95 missed the consensus estimate of $1.97, leading to diminished investor confidence.
- Commodity Market Fluctuations: Oil prices dipped 0.3% to $63.08, while gold rose 1.6% to $4,969.10, indicating increased demand for safe-haven assets, and copper saw a slight increase of 0.4% to $5.8460, reflecting stable industrial demand.
See More
Ernexa Therapeutics Prices Public Offering at $0.50 per Share
- Offering Size: Ernexa Therapeutics announced a public offering of 21,000,000 shares at a price of $0.50 per share, expected to generate approximately $10.5 million in gross proceeds, which will be utilized to advance development programs and for general corporate purposes.
- Warrant Details: The accompanying warrants have an exercise price of $0.68 per share, are exercisable upon issuance, and will expire either five years after the initial issuance or 180 days following the release of clinical trial data, potentially adding another $14.3 million in gross proceeds if fully exercised.
- Underwriter Role: Brookline Capital Markets is acting as the exclusive placement agent for the offering, facilitating the capital raise to support Ernexa's innovative therapeutic solutions and ensuring the funds are secured for ongoing development.
- Technological Background: Ernexa focuses on developing cell therapies for advanced cancer and autoimmune diseases, leveraging engineered induced pluripotent stem cells (iPSCs) to provide scalable, off-the-shelf treatment solutions, highlighting significant market potential in the healthcare sector.
See More
Ernexa Therapeutics Advances Cell Therapy for Cancer Treatment
- Successful FDA Meeting: Ernexa Therapeutics recently held a successful Pre-IND meeting with the U.S. FDA, receiving regulatory alignment on its lead cell therapy ERNA-101, paving the way for an Investigational New Drug application and anticipated clinical trials in the second half of 2026.
- Accelerated Technology Transfer: The company has initiated technology transfer for clinical-grade manufacturing, which not only speeds up operational readiness but also lays a solid foundation for clinical testing of ERNA-101, demonstrating Ernexa's forward-looking strategy in cell therapy.
- Innovative Cell Therapy: ERNA-101 is designed to activate and regulate the immune system to recognize and attack cancer cells, representing Ernexa's core technology in treating ovarian cancer and autoimmune diseases, with significant market potential.
- New Treatment Solutions: Ernexa's synthetic allogeneic induced mesenchymal stem cells (iMSCs) provide a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting, marking a significant advancement in cell therapy.
See More
Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%
- Earnings Beat: Penguin Solutions reported Q1 earnings of $0.49 per share, surpassing analyst expectations of $0.44, indicating robust profitability that may attract more investor interest.
- Sales Growth: The company achieved quarterly sales of $343.071 million, exceeding the analyst consensus of $338.758 million, reflecting strong market demand and potential for sustained growth.
- Stock Price Surge: Following the earnings report, Penguin Solutions' shares rose 5.3% to $22.70 in pre-market trading, demonstrating a positive market reaction to its financial performance.
- Increased Market Confidence: The positive results not only bolster investor confidence but may also enhance the company's prospects for better terms in future financing and expansion plans.
See More
Ernexa Therapeutics Targets 2026 for First-in-Human Ovarian Cancer Trial
- Regulatory Alignment Achieved: Ernexa Therapeutics received positive feedback during its Pre-IND meeting with the FDA, establishing a clear pathway for IND submission and aiming to initiate its first-in-human ovarian cancer trial in the second half of 2026, marking a significant advancement in cancer treatment.
- Accelerated Tech Transfer: The company has commenced critical tech transfer, a milestone that will expedite the preparation of clinical-grade materials, ensuring efficient operations ahead of clinical trials and enhancing its competitive edge in the cell therapy market.
- Clear Product Focus: Ernexa's lead clinical product, ERNA-101, targets ovarian cancer, a field with limited effective therapies and high recurrence rates, positioning the company to address unmet patient needs with its innovative treatment approach.
- Strategic Vision Defined: By developing synthetic allogeneic induced mesenchymal stem cells (iMSCs), Ernexa not only enhances treatment accessibility but also lays the groundwork for future product line expansions, showcasing the company's long-term growth potential in the cell therapy sector.
See More
